Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy

Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer

(2013) S Boeck et al.   BRITISH JOURNAL OF CANCER

Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy

(2012) Yvonne Nadine Fahmueller et al.   BMC CANCER

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy

(2012) Oliver J Stoetzer et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients

(2012) Yvonne Nadine Fahmueller et al.   INTERNATIONAL JOURNAL OF CANCER

Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy

(2012) Nikolaus Kohles et al.   TUMOR BIOLOGY

Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients

(2011) Nikolaus Kohles et al.   BMC CANCER

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

(2011) Oliver Kepp et al.   CANCER AND METASTASIS REVIEWS

2011: the immune hallmarks of cancer

(2011) Federica Cavallo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

High-mobility group box 1 and cancer

(2010) Daolin Tang et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Analysis and verification of the HMGB1 signaling pathway

(2010) Haijun Gong et al.   BMC BIOINFORMATICS

Decoding Cell Death Signals in Inflammation and Immunity

(2010) Laurence Zitvogel et al.   CELL

Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer

(2010) S. Boeck et al.   CLINICAL CANCER RESEARCH

Plasma Nucleosome Levels Might Predict Response to Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Sachin Kumar et al.   Clinical Lung Cancer

Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer

(2010) Michael Haas et al.   TUMOR BIOLOGY

The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival

(2009) R Kang et al.   CELL DEATH AND DIFFERENTIATION

Clinical Value of Serum HMGB1 Levels in Early Detection of Recurrent Squamous Cell Carcinoma of Uterine Cervix: Comparison with Serum SCCA, CYFRA21-1, and CEA Levels

(2009) Xiugui Sheng et al.   CROATIAN MEDICAL JOURNAL

Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy.

(2009) Wojciech Naumnik et al.   FOLIA HISTOCHEMICA ET CYTOBIOLOGICA

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

(2009) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer

(2009) Guan-Hong Shang et al.   RESPIRATORY MEDICINE

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

(2008) Volker Heinemann et al.   BMC CANCER

Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma

(2008) B.-Q. Cheng et al.   DIGESTIVE AND LIVER DISEASE